Tadaaki Yamada Selected Research

Tadaaki Yamada Research Topics

Disease

94	Neoplasms (Cancer) 03/2024 - 06/2008
73	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2024 - 12/2006
49	Lung Neoplasms (Lung Cancer) 03/2024 - 11/2009
18	Neoplasm Metastasis (Metastasis) 11/2023 - 11/2004
10	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2023 - 01/2009
8	Adenocarcinoma of Lung 04/2023 - 01/2013
8	Opioid-Induced Constipation 01/2021 - 01/2017
7	Malignant Mesothelioma 10/2015 - 06/2008
6	Disease Progression 01/2024 - 06/2018
6	Cachexia 11/2023 - 01/2021
6	Carcinoma (Carcinomatosis) 01/2023 - 06/2011
5	Pleural Effusion (Pleural Effusions) 06/2023 - 06/2008
4	Brain Neoplasms (Brain Tumor) 01/2023 - 12/2017
4	Lung Injury 09/2022 - 01/2007
4	Cancer Pain 01/2021 - 01/2017
3	Pain (Aches) 10/2019 - 12/2017
3	Peritoneal Neoplasms 12/2017 - 06/2011
3	Meningeal Carcinomatosis 01/2017 - 10/2009
2	Mesothelioma 03/2024 - 09/2011
2	Asthma (Bronchial Asthma) 05/2023 - 10/2004
2	Pericardial Effusion 11/2021 - 01/2019
2	Carcinogenesis 05/2021 - 01/2018
2	Gastrointestinal Diseases (Functional Gastrointestinal Disorders) 01/2020 - 01/2017
2	Thrombocytopenia (Thrombopenia) 01/2020 - 12/2018
2	Hypoxia (Hypoxemia) 03/2019 - 04/2007
2	Constipation 01/2019 - 05/2018
2	Adenocarcinoma 11/2018 - 10/2009
2	Small Cell Carcinoma 01/2018 - 10/2009

Drug/Important Bio-Agent (IBA)

42	Tyrosine Kinase InhibitorsIBA 06/2023 - 11/2009
41	ErbB Receptors (EGF Receptor)IBA 06/2023 - 11/2009
22	Immune Checkpoint InhibitorsIBA 01/2024 - 01/2019
20	osimertinibIBA 06/2023 - 01/2016
18	Gefitinib (Iressa)FDA Link 01/2023 - 11/2009
16	Erlotinib Hydrochloride (CP 358,774)FDA Link 06/2023 - 11/2009
12	Phosphotransferases (Kinase)IBA 10/2023 - 07/2011
11	Proteins (Proteins, Gene)FDA Link 10/2023 - 01/2007
11	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 12/2017 - 01/2010
10	Docetaxel (Taxotere)FDA Link 03/2024 - 12/2006
10	CrizotinibIBA 01/2019 - 07/2012
9	LigandsIBA 11/2023 - 06/2011
8	RamucirumabIBA 03/2024 - 06/2018
8	pembrolizumabIBA 11/2023 - 06/2020
8	B7-H1 AntigenIBA 10/2023 - 08/2019
8	naldemedineIBA 01/2021 - 01/2017
8	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 06/2008
7	AntibodiesIBA 03/2024 - 12/2011
7	Anaplastic Lymphoma KinaseIBA 01/2023 - 07/2012
6	AfatinibIBA 01/2022 - 03/2012
6	Opioid Analgesics (Opioids)IBA 01/2020 - 01/2017
5	PlatinumIBA 01/2024 - 01/2020
5	CytokinesIBA 01/2023 - 01/2007
5	NivolumabIBA 11/2022 - 05/2020
5	Cisplatin (Platino)FDA LinkGeneric 09/2012 - 12/2006
4	Etoposide (VP 16)FDA LinkGeneric 10/2023 - 10/2009
4	lenvatinibIBA 09/2023 - 12/2009
4	Paclitaxel (Taxol)FDA LinkGeneric 10/2022 - 01/2019
4	Carboplatin (JM8)FDA LinkGeneric 01/2020 - 10/2009
4	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2020 - 07/2012
4	Narcotic Antagonists (Opioid Antagonists)IBA 01/2020 - 01/2017
4	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2019 - 07/2011
3	Small Interfering RNA (siRNA)IBA 03/2024 - 10/2014
3	Messenger RNA (mRNA)IBA 03/2024 - 06/2011
3	durvalumabIBA 12/2023 - 01/2020
3	RNA (Ribonucleic Acid)IBA 02/2023 - 01/2007
3	lorlatinibIBA 01/2023 - 01/2019
3	dacomitinibIBA 01/2023 - 08/2019
3	alectinibIBA 11/2021 - 07/2014
3	Histone Deacetylase InhibitorsIBA 01/2020 - 01/2018
3	Gemcitabine FDA Link 01/2020 - 01/2009
3	Bevacizumab (Avastin)FDA Link 01/2019 - 01/2009
3	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 01/2017 - 07/2012
3	WZ4002IBA 01/2013 - 03/2012
2	C-Reactive ProteinIBA 09/2023 - 04/2023
2	Growth Differentiation Factor 15IBA 04/2023 - 01/2023
2	AlbuminsIBA 04/2023 - 01/2021
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2023 - 10/2020
2	130-nm albumin-bound paclitaxelIBA 10/2022 - 10/2018
2	EnzymesIBA 09/2022 - 01/2021
2	amrubicinIBA 09/2022 - 01/2020
2	Adrenal Cortex Hormones (Corticosteroids)IBA 11/2021 - 05/2005
2	Superoxide DismutaseIBA 05/2021 - 04/2007
2	AndrogensIBA 01/2021 - 01/2017
2	testosterone enanthate (Delatestryl)FDA LinkGeneric 01/2021 - 01/2017
2	N- (2- fluoro- 4- ((2- (4- (4- methylpiperazin- 1- yl)piperidin- 1- yl)carbonylaminopyridin- 4- yl)oxy)phenyl)- N'- (4- fluorophenyl)cyclopropane- 1,1- dicarboxamideIBA 01/2020 - 07/2017
2	Angiogenesis InhibitorsIBA 03/2019 - 06/2018
2	Vinorelbine (Navelbine)FDA LinkGeneric 01/2019 - 08/2010
2	Cytotoxins (Cytolysins)IBA 01/2019 - 01/2019
2	LaxativesIBA 01/2019 - 12/2017
2	Biomarkers (Surrogate Marker)IBA 12/2018 - 01/2017
2	entrectinibIBA 01/2018 - 12/2017
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2018 - 01/2017
2	tyrosine receptor (receptor, tyrosine)IBA 01/2018 - 07/2013

Therapy/Procedure

58	Therapeutics 03/2024 - 04/2007
34	Drug Therapy (Chemotherapy) 03/2024 - 01/2009
10	Immunotherapy 10/2023 - 01/2019
4	Radiotherapy 09/2022 - 12/2006
3	Chemoradiotherapy 12/2023 - 01/2020
2	Combination Drug Therapy (Combination Chemotherapy) 01/2021 - 08/2010
2	Aftercare (After-Treatment) 06/2020 - 09/2012
2	Molecular Targeted Therapy 01/2019 - 01/2018